Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	3.13B
Revenue (ttm)	446.26M
Net Income (ttm)	34.56M
Shares Out	90.79M
EPS (ttm)	0.38
PE Ratio	90.75
Forward PE	n/a
Dividend	0.09 (0.26%)
Ex-Dividend Date	Jun 12, 2025

Volume	9,041,500
Average Volume	5,692,803
Open	34.05
Previous Close	34.50
Day's Range	33.95 - 34.84
52-Week Range	19.63 - 39.28
Beta	0.55
RSI	57.36
Earnings Date	Aug 22, 2025

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China. It primarily focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, and Phosphatidylcholine series of products. Its products are primarily used in medicines, dietary supplements, cosmetics, and other fields. The company also exports its products to Europe, America, Southeast Asia, and other countries. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 1997 and is based in Changshu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 524
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2024, SHE:301258's revenue was 429.47 million, a decrease of -12.23% compared to the previous year's 489.29 million. Earnings were 16.41 million, a decrease of -85.38%.